Chronic GVHD as an autoimmune disease

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 2, 2008, Pages 281-289

  Tyndall, Alan ^a   Dazzi, Francesco ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

autoimmune disease; chronic graft versus host; tolerance

Indexed keywords

ALEMTUZUMAB; ANTIRHEUMATIC AGENT; AUTOIMMUNE REGULATOR PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA B27 ANTIGEN; INTERLEUKIN 1; KERATINOCYTE GROWTH FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTATION; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DONOR LYMPHOCYTE INFUSION; GENETIC PREDISPOSITION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INCIDENCE; IPEX SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; MICE;

EID: 44049102719     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.03.003     Document Type: Review

References (43)

1. Hampe J., Grebe J., Nikolaus S., et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 359 (2002) 1661-1665
2. Brewerton D.A., Hart F.D., Nicholls A., et al. Ankylosing spondylitis and HL-A 27. Lancet 1 (1973) 904-907
3. Sestak A.L., Nath S.K., Sawalha A.H., et al. Current status of lupus genetics. Arthritis Research & Therapy 9 (2007) 210
4. Vossenaar E.R., and van Venrooij W.J. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Research & Therapy 6 (2004) 107-111
5. Kraan M.C., Versendaal H., Jonker M., et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis and Rheumatism 41 (1998) 1481-1488
6. Fourneau J.M., Bach J.M., van Endert P.M., et al. The elusive case for a role of mimicry in autoimmune diseases. Molecular Immunology 40 (2004) 1095-1102
7. Boursalian T.E., and Bottomly K. Survival of naive CD4 T cells: roles of restricting versus selecting MHC class II and cytokine milieu. Journal of Immunology 162 (1999) 3795-3801
8. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
9. Lang K.S., Recher M., Junt T., et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nature Medicine 11 (2005) 138-145
10. Hill G.R., Crawford J.M., Cooke K.R., et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
11. Chen X., Vodanovic-Jankovic S., Johnson B., et al. Absence of regulatory T cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft versus host disease. Blood 110 (2007) 3804-3813
12. Nagamine K., Peterson P., Scott H.S., et al. Positional cloning of the APECED gene. Nature Genetics 17 (1997) 393-398
13. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genetics 27 (2001) 20-21
14. Hirota K., Hashimoto M., Yoshitomi H., et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. The Journal of Experimental Medicine 204 (2007) 41-47
15. Nguyen L.T., Jacobs J., Mathis D., et al. Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis and Rheumatism 56 (2007) 509-520
16. Hoffmann P., Ermann J., Edinger M., et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. The Journal of Experimental Medicine 196 (2002) 389-399
17. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk ofGVHD following HLA-matched allogeneic SCT. Blood 108 (2006) 1291-1297
18. Nadal E., Garin M., Kaeda J., et al. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 21 (2007) 472-479
19. Martinon F., Burns K., and Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Molecular Cell 10 (2002) 417-426
20. Conti B.J., Davis B.K., Zhang J., et al. CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. The Journal of Biological Chemistry 280 (2005) 18375-18385
21. Bhat A., Naguwa S.M., and Gershwin M.E. Genetics and new treatment modalities for familial mediterranean Fever. Annals of the New York Academy of Sciences 1110 (2007) 201-208
22. Imirzalioglu N., Dursun A., Tastan B., et al. MEFV gene is a probable susceptibility gene for Behcet's disease. Scandinavian Journal of Rheumatology 34 (2005) 56-58
23. Isenberg D.A., Manson J.J., Ehrenstein M.R., et al. Fifty years of anti-ds DNA antibodies: are we approaching journey's end?. Rheumatology (Oxford) 46 (2007) 1052-1056
24. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Medicine 8 (2002) 575-581
25. Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95 (2000) 67-71
26. Billiau A.D., Fevery S., Rutgeerts O., et al. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood 100 (2002) 1894-1902
27. Fozza C., Szydlo R.M., Abdel-Rehim M.M., et al. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. British Journal of Haematology 136 (2007) 833-836
28. Dickinson A.M. Risk assessment in haematopoietic stem cell transplantation: pre-transplant patient and donor factors: non-HLA genetics. Best Practice & Research. Clinical Haematology 20 (2007) 189-207
29. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999) 412-415
30. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
31. Vogelsang G.B. How I treat chronic graft-versus-host disease. Blood 97 (2001) 1196-1201
32. Sprent J., and Kishimoto H. The thymus and central tolerance. Transplantation 72 (2001) S25-S28
33. Dutt S., Tseng D., Ermann J., et al. Naive and Memory T Cells Induce Different Types of Graft-versus-Host Disease. Journal of Immunology 179 (2007) 6547-6554
34. Panoskaltsis-Mortari A., Lacey D.L., Vallera D.A., et al. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92 (1998) 3960-3967
35. Blazar B.R., Weisdorf D.J., Defor T., et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 108 (2006) 3216-3222
36. Zhang C., Todorov I., Zhang Z., et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 107 (2006) 2993-3001
37. Daikeler T., and Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Practice & Research. Clinical Haematology 20 (2007) 349-360
38. King C., Ilic A., Koelsch K., et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117 (2004) 265-277
39. Trendelenburg M., Gregor M., Passweg J., et al. 'Altered immunity syndrome', a distinct entity in long-term bone marrow transplantation survivors?. Bone Marrow Transplantation 28 (2001) 1175-1176
40. McKendry R.J., Huebsch L., and Leclair B. Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year followup. Arthritis & Rheumatism 39 (1996) 1246-1253
41. Sturfelt G., Lenhoff S., Sallerfors B., et al. Transplantation with allogenic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor. Annals of the Rheumatic Diseases 55 (1996) 638-641
42. Nelson J.L., Furst D.E., Maloney S., et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 351 (1998) 559-562
43. Stevens A.M., Tsao B.P., Hahn B.H., et al. Maternal HLA class II compatibility in men with systemic lupus erythematosus. Arthritis & Rheumatism 52 (2005) 2768-2773